New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:05 EDTALNYAlnylam, collaborators present new clinical data for patisiran
Alnylam Pharmaceuticals and collaborators announced new clinical data for patisiran, an RNAi therapeutic targeting transthyretin in development for the treatment of TTR-mediated amyloidosis. These data are being presented at the International Symposium on Amyloidosis held April 27 – May 1 in Indianapolis, Indiana. First, the company presented updated Phase 2 results in patients with Familial Amyloidotic Polyneuropathy confirming robust TTR knockdown of up to 96% with a mean TTR knockdown of approximately 80%. Further, Alnylam presented preliminary results from the open-label extension study with patisiran in patients that were enrolled in the Phase 2 study. Preliminary results from the OLE study showed that multiple doses of patisiran achieved sustained knockdown of serum TTR protein levels at the 80% target level through 168 days. Moreover, OLE results showed a favorable tolerability profile with up to eight doses administered. Finally, the company presented results of a natural history, cross-sectional analysis study of 283 FAP patients aimed at measuring the rate of neuropathy progression and its correlation with disease severity. These results provide support for Alnylam’s Phase 3 APOLLO trial where patisiran is being evaluated for its potential efficacy and safety in the FAP indication.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
08:10 EDTALNYAlnylam, The Medicines Co. file application to initiate Phase 1 ALN-PCSsc study
Subscribe for More Information
October 27, 2014
07:04 EDTALNYAlnylam management to meet with Deutsche Bank
Subscribe for More Information
October 21, 2014
09:48 EDTALNYShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use